Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep:78:134-137.
doi: 10.1016/j.parkreldis.2020.08.012. Epub 2020 Aug 13.

Predictors of COVID-19 outcome in Parkinson's disease

Alfonso Fasano  1 , Antonio E Elia  2 , Carlo Dallocchio  3 , Margherita Canesi  4 , Dario Alimonti  5 , Chiara Sorbera  6 , Araceli Alonso-Canovas  7 , Gianni Pezzoli  8
Affiliations

Predictors of COVID-19 outcome in Parkinson's disease

Alfonso Fasano et al. Parkinsonism Relat Disord. 2020 Sep.

Abstract

Introduction: Specific pre-existing medical conditions (e.g. hypertension or obesity), advanced age and male sex appear linked to more severe manifestations of SARS Co-V2 infection, thus raising the question of whether Parkinson's disease (PD) poses an increased risk of morbidity and mortality in COVID-19 patients.

Methods: In order to describe the outcome of COVID-19 in multi-centre a cohort of PD patients and explore its potential predictors, we gathered the clinical information of 117 community-dwelling patients with COVID-19 followed in 21 tertiary centres in Italy, Iran, Spain, and the UK.

Results: Overall mortality was 19.7%, with a significant effect of co-occurrence of dementia, hypertension, and PD duration.

Conclusions: The frailty caused by advanced PD poses an increased risk of mortality during COVID-19.

Keywords: COVID-19; Dementia; Outcome; Parkinson's disease.

PubMed Disclaimer

Conflict of interest statement

AF received honoraria from Abbvie, Abbott, Medtronic, Boston Scientific, UCB, Ipsen and research support from Abbvie, Medtronic, and Boston Scientific.

Other authors have no disclosures.

Figures

Fig. 1
Fig. 1
A. Mortality rate according to age group and sex in the total sample of 117 patients. B. Mortality rate according to Parkinson's disease duration in the total sample and the selected sample of 53 patients with hypertension and/or dementia (comorbidities).
See this image and copyright information in PMC

References

    1. Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X., Cheng Z., Yu T., Xia J., Wei Y., Wu W., Xie X., Yin W., Li H., Liu M., Xiao Y., Gao H., Guo L., Xie J., Wang G., Jiang R., Gao Z., Jin Q., Wang J., Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. - PMC - PubMed
    1. Filatov A., Sharma P., Hindi F., Espinosa P.S. Neurological complications of coronavirus disease (COVID-19): encephalopathy. Cureus. 2020;12 - PMC - PubMed
    1. Antonini A., Leta V., Teo J., Chaudhuri K.R. Outcome of Parkinson's Disease patients affected by COVID-19. Mov. Disord. 2020 - PMC - PubMed
    1. Tomlinson C.L., Stowe R., Patel S., Rick C., Gray R., Clarke C.E. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov. Disord. 2010;25:2649–2653. - PubMed
    1. Schirinzi T., Cerroni R., Di Lazzaro G., Liguori C., Scalise S., Bovenzi R., Conti M., Garasto E., Mercuri N.B., Pierantozzi M., Pisani A., Stefani A. Self-reported needs of patients with Parkinson's disease during COVID-19 emergency in Italy. Neurol. Sci. 2020;41:1373–1375. - PMC - PubMed

MeSH terms

Substances